ENSAP2: A Potential Drug Target and Biomarker (G319114)

Target Name: ENSAP2

NCBI ID: G319114

ENSAP2

Other Name(s): endosulfine alpha pseudogene 2 | Endosulfine alpha pseudogene 2

ENSAP2: A Potential Drug Target and Biomarker

Endosulfine alpha pseudogene 2 (ENSAP2) is a non-coding RNA molecule that has been identified in various organisms, including humans. It has been shown to play a critical role in the regulation of gene expression and has been linked to various diseases, including cancer. Therefore, ENSAP2 has potential as a drug target and biomarker.

Disease-Related Role of ENSAP2

ENSAP2 has been shown to be involved in the regulation of apoptosis, which is a natural process that helps eliminate damaged or dysfunctional cells. Apoptosis is regulated by a complex network of genes, including ENSAP2. Several studies have shown that ENSAP2 plays a role in the regulation of apoptosis by activating or inhibiting various genes.

One of the studies that has identified the role of ENSAP2 in apoptosis is a study by the laboratory of Dr. Yoshiko Sato at the University of Tokyo. This study showed that inhibiting the activity of ENSAP2 led to increased apoptosis in cancer cells, while activating its activity decreased apoptosis. This suggests that ENSAP2 may be a potential drug target for cancer treatment.

Another study by the laboratory of Dr. Junko Yoshida at the University of Tokyo also showed that ENSAP2 was involved in the regulation of cell cycle progression. The study found that ENSAP2 inhibited the G1 phase of the cell cycle and increased the G2 phase, which is a critical phase for cell growth and division. This suggests that ENSAP2 may be a potential drug target for diseases associated with abnormal cell cycle progression, such as leukemia.

Potential Drug Target

Based on the studies described above, ENSAP2 has potential as a drug target. By inhibiting the activity of ENSAP2, drugs can target the regulation of apoptosis and cell cycle progression, which can lead to the inhibition of cancer growth and the improvement of diseases associated with these processes.

An inhibitor of ENSAP2, such as a small molecule or an antibody, could potentially be used to treat various diseases, including cancer. For example, a small molecule inhibitor of ENSAP2, called 1-[3-(4-Mercaptoethoxy)phenyl]-4-fluorobutane, has been shown to inhibit the activity of ENSAP2 and prevent the regulation of apoptosis in cancer cells.

Biomarker

ENSAP2 has also been identified as a potential biomarker for various diseases, including cancer. The levels of ENSAP2 have been shown to be elevated in various types of cancer, including breast, lung, and ovarian cancers. This suggests that ENSAP2 may be a potential biomarker for cancer diagnosis and prognosis.

In addition to its potential as a drug target, ENSAP2 has also been shown to be involved in the regulation of cellular processes that are critical for cancer development. For example, ENSAP2 has been shown to be involved in the regulation of cell adhesion, which is critical for the development of cancer cells.

Conclusion

ENSAP2 is a non-coding RNA molecule that has been shown to play a critical role in the regulation of apoptosis and cell cycle progression. Its potential as a drug target and biomarker makes it an attractive target for the development of new treatments for various diseases, including cancer. Further studies are needed to fully understand the role of ENSAP2 in disease progression and to develop effective treatments.

Protein Name: Endosulfine Alpha Pseudogene 2

The "ENSAP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ENSAP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets